MedTrace Logo

Papilloma Virus Vaccine Therapy in Treating Young Patients With Recurrent Papilloma of the Larynx

NCT00002454 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2011-07-26

No results posted yet for this study

Summary

RATIONALE: Vaccines made from papilloma virus cells may make the body build an immune response to and kill papilloma cells.

PURPOSE: Phase II trial to study the effectiveness of papilloma virus vaccine in treating young patients with recurrent papilloma of the larynx.

Conditions

  • Precancerous Condition

Interventions

BIOLOGICAL

autologous tumor cell vaccine

Sponsors & Collaborators

  • University of Medicine and Dentistry of New Jersey

    lead OTHER

Principal Investigators

  • James M. Oleske, MD · Rutgers, The State University of New Jersey

Study Design

Purpose
TREATMENT

Eligibility

Min Age
1 Year
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1971-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00002454 on ClinicalTrials.gov